Skip to main content

ATOSSA THERAPEUTICS INC

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Condensed Consolidated Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

March 31, 2024December 31, 2023
Assets
Current assets
Cash and cash equivalents$83,960$88,460
Restricted cash110110
Prepaid materials1,3721,487
Prepaid expenses and other current assets1,6132,162
Total current assets87,05592,219
Investment in equity securities1,7101,710
Other assets2,3222,323
Total assets$91,087$96,252
Liabilities and stockholders' equity
Current liabilities
Accounts payable$1,230$806
Accrued expenses1,613973
Payroll liabilities6591,654
Other current liabilities1,8261,803
Total current liabilities5,3285,236
Total liabilities5,3285,236
Commitments and contingencies (Note 13)
Stockholders' equity
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of March 31, 2024 and December 31, 2023——
Common stock - $0.18 par value; 175,000,000 shares authorized; 125,507,814 and 125,304,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively22,82922,792
Additional paid-in capital256,571255,987
Treasury stock, at cost; 1,320,046 shares of common stock at March 31, 2024 and December 31, 2023(1,475)(1,475)
Accumulated deficit(192,166)(186,288)
Total stockholders' equity85,75991,016
Total liabilities and stockholders' equity$91,087$96,252
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.